Trial · NCT05125224
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
NCT05125224, Completed, Brigham and Women's Hospital; results first posted 2025-11-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide. Trials, record NCT05125224. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05125224
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
- NCT number
- NCT05125224
- Status
- Completed
- Enrollment
- 163,720 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Hypertension
- Interventions
- Dihydropyridine calcium channel blocker, Hydrochlorothiazide
- First posted
- 2021-11-18
- Last updated
- 2025-11-06
- Results first posted
- 2025-11-06
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Dementia Onset | Median follow up times: 1) 189 days (exp), 171 days (ref) 2) 835 days (exp). 851 days (ref) 3) 388 days (exp), 348 days (ref) 4) 191 days (exp), 172 days (ref) | Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Dementia Onset | Median follow up times: 1) 189 days (exp), 171 days (ref) 2) 835 days (exp). 851 days (ref) 3) 388 days (exp), 348 days (ref) 4) 191 days (exp), 172 days (ref) | Incidence rate per 1000 person year | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Dementia Onset | Dihydropyridine calcium channel blocker | Analysis 1 | 17.1 | 95% Confidence Interval 16.2 to 18.0 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Hydrochlorothiazide | Analysis 1 | 13.7 | 95% Confidence Interval 12.8 to 14.6 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Dihydropyridine calcium channel blocker | Analysis 2 | 20.8 | 95% Confidence Interval 19.8 to 21.9 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Hydrochlorothiazide | Analysis 2 | 20.6 | 95% Confidence Interval 19.6 to 21.6 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Dihydropyridine calcium channel blocker | Analysis 3 | 15.6 | 95% Confidence Interval 14.6 to 16.7 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Hydrochlorothiazide | Analysis 3 | 13.1 | 95% Confidence Interval 12.1 to 14.2 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Dihydropyridine calcium channel blocker | Analysis 4 | 5.6 | 95% Confidence Interval 5.1 to 6.2 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Hydrochlorothiazide | Analysis 4 | 4.0 | 95% Confidence Interval 3.6 to 4.6 | Incidence rate per 1000 person year |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dihydropyridine calcium channel blocker | 77,152 | |
| Overall Study | STARTED | Hydrochlorothiazide | 86,568 | |
| Overall Study | COMPLETED | Dihydropyridine calcium channel blocker | 64,254 | |
| Overall Study | COMPLETED | Hydrochlorothiazide | 64,254 | |
| Overall Study | NOT COMPLETED | Dihydropyridine calcium channel blocker | 12,898 | |
| Overall Study | NOT COMPLETED | Hydrochlorothiazide | 22,314 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dihydropyridine calcium channel blocker | 0 | 64,254 |
| Total, all-cause mortality | Hydrochlorothiazide | 0 | 64,254 |
| Total, other adverse events | Dihydropyridine calcium channel blocker | 0 | 64,254 |
| Total, other adverse events | Hydrochlorothiazide | 0 | 64,254 |
| Total, serious adverse events | Dihydropyridine calcium channel blocker | 0 | 0 |
| Total, serious adverse events | Hydrochlorothiazide | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Dihydropyridine calcium channel blocker vs Hydrochlorothiazide: deaths from any cause |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05125224
GET https://conductscience.org/api/trials/v1/NCT05125224/registered